Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about FENC, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Sodium Thiosulfate FDA approved Sep 2022 · Pedmark |
Cisplatin-Induced Hearing Loss in Children Who Had Standard-risk… | N/A · NCT04132882 | Available |
| Pedmark® STS | Solid Tumor Malignancies | Phase 1/2 · NCT07407582 | Recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
FENC holds $48.7M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 14 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when FENC files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | 5%+ holder (13G) | 3,321,333 | 9.41% | 2026-06-30 |
| Orin Hirschman | Institution (13G, 5%+) | 2,499,421 | 7.08% | 2026-09-30 |
| Robert Andrade CHIEF FINANCIAL OFFICER · +779,330 options |
Insider | 248,558 | 0.70% | 2026-10-31 |
| Rosty Raykov Former Director |
Insider | 124,411 | 0.35% | 2026-08-31 |
| Jeffrey S. Hackman Chief Executive Officer, Director |
Insider | 70,844 | 0.20% | 2026-10-31 |
| Chris A Rallis Director · +200,000 options |
Insider | 63,077 | 0.18% | 2026-05-11 |
| Christiana Marie Cioffi Chief Strategy Officer |
Insider | 28,902 | 0.08% | 2026-10-31 |
| Terry L Evans Chief Commercial Officer |
Insider | 24,181 | 0.07% | 2026-10-31 |
| Pierre Sargis Sayad Chief Medical Officer |
Insider | 13,701 | 0.04% | 2026-10-31 |
Share count 35,305,117 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for FENC and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →